First MitraClip™ Procedure Performed Using the All-in-One VersaCross™ Transseptal Solution

My Subscriptions

Payment Confirmation

Transaction Failed

Your transaction failed, please try again or contact site support.

The first MitraClip™ procedure was performed using the VersaCross™ Transseptal Solution was performed by Dr. William Gray, System Chief of Cardiovascular Diseases for Main Line Health, and president, Lankenau Heart Institute, in Wynnewood, Pennsylvania. The VersaCross solution is the world’s first all-in-one left-heart access device featuring an atraumatic RF-tipped pigtail wire. The device is designed to achieve left-heart access with controlled precision, while reducing the number of exchanges throughout the procedure by serving as an exchange wire once access is achieved.

The puncture wire features Baylis’ signature RF puncture technology, which aims to facilitate smooth and precise transseptal procedures. The VersaCross solution also includes the first shapeable sheath and dilator, further allowing transseptal punctures to occur at the optimal location on the septum.

“Structural heart procedures requiring transseptal approaches demand a very precise puncture location to optimize therapy delivery. Traditionally, this requires the use of multiple devices in a step-wise method,” said Dr. Gray. “If the optimal location is not achieved on first-pass, we are required to return to the starting point, which involves the time consuming and potentially riskier reintroduction of multiple devices. This new device enables a novel technique which minimizes the need for exchanges and streamlines transseptal access while achieving the optimal puncture location.”

The VersaCross solution has a sturdy 0.035″ exchange rail, eliminating the need for additional devices to achieve reliable delivery of large sheaths. It facilitates efficient transseptal procedures by reducing the overall number of device exchanges.

“The VersaCross solution serves transseptal procedures from start to finish, by combining a versatile wire and sheath with the precision of Baylis’ RF puncture technology,” said Robert Harrison, Director of Research and Development, Cardiology, at Baylis Medical. “It is a true embodiment of the Baylis mandate to provide physicians with meaningful advancements in transseptal access, for the sake of improved patient care.”

The VersaCross platform is also available in a J-tip wire and can be paired with a range of sheaths tailored to individual needs. The device is expected to commercially launch early 2020.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.